Figures computed from official regulatory filings — .
Analysttarget 3.33 USD (+195%) · consensus 4.2/5 · 3 buy · 2 hold · 0 sell
Ownershipinsiders 14.42% · institutions 67.56% · short 5.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ADC TELECOMMUNICATIONS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
17 buys11 sellsbar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| OWEN LAURA N | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Jurasek Christopher | Other | $232.1K | SEC |
| PFLAUM JEFFREY D | Other | $479.1K | Unusual size | SEC |
| Parran Richard B JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| PFLAUM JEFFREY D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BOYLE JOHN J III | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| SWITZ ROBERT E | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| PFLAUM JEFFREY D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Parran Richard B JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| WANGBERG LARRY W | Other | $9.1K | SEC |
| PFLAUM JEFFREY D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Nemitz Steven Gary | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Rehfeld John Etrack record | OtherD (derivative) | $432.3K | SEC |
| OWEN LAURA N | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Nemitz Steven Gary | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BOYLE JOHN J III | OtherD (derivative) | $136.3K | SEC |
| MATHEWS JAMES G | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| OBRIEN PATRICK D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| OBRIEN PATRICK D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| PFLAUM JEFFREY D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| WANGBERG LARRY W | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BOYLE JOHN J III | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| PFLAUM JEFFREY D | Other | $45.1K | Unusual size | SEC |
| MATHEWS JAMES G | OtherD (derivative) | $619.3K | Unusual size | SEC |
| WUNSCH JOHN D | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |